2. Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, Denmark
3. Inselspital, Bern Universitatsspital, Bern, Switzerland
4. Deutsches Herzzentrum Munchen, Munich, Germany
5. St Thomas Hospital, London, UK
6. Centre Hospitalier Universitaire de Charleroi, Charleroi, Belgium
7. Inselspital, Bern Universitatsspital, Bern, Switzerland
8. Deutsches Herzzentrum Munchen, Munich, Germany
9. St Thomas Hospital, London, UK
10. Inselspital, Bern Universitatsspital, Bern, Switzerland
11. St Thomas Hospital, London, UK
12. Emory University Hospital, Atlanta, USA
13. Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
As a public service to our readership, this article - peer reviewed by the Editors of EuroIntervention - has been published immediately upon acceptance as it was received. The content of this article is the sole responsibility of the authors, and not that of the journal or its publishers.
Please note that supplementary movies are not available online at this stage. Once a paper is published in its edited and formatted form, it will be accompanied online by any supplementary movies.
To read the full content of this article, please download the PDF. Download full article (PDF)
Methods and results:. Data on 50 patients treated by transcaval TAVI in five European centres were collected and analysed according to the Valve Academic Research Consortium (VARC)-2 definitions. The study population had a mean age of 78.7 ± 8.0 years and a high surgical risk profile (median STS risk score 6.1%, interquartile range 3.0%-11.2%). Transcaval access was successful in 49 of 50 patients and device success was obtained in 94% of cases. Closure of the caval-aortic puncture site with a nitinol cardiac occluder was successful in all cases without need for emergent surgery. One patient received additional sealing of the aortic puncture site with a covered stent one day post-TAVI due to a gradual haemoglobin drop of 3 g/dL. VARC-2-defined life-threatening bleeding and major vascular complications possibly related to transcaval access were 4% and 10%, respectively. There were no bleeding or vascular complications after discharge. At 30 days, the clinical efficacy endpoint was reached in 88% of patients.
Conclusions:. Transfemoral transcaval access proofs to be a feasible and safe TAVI approach for high-risk patients with severe aortic stenosis not suitable for transfemoral or transaxillary/subclavian transarterial access.
Sign in to read and download the full articleForgot your password?
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com